Michael Schmertzler
Known title: DirectorCIK: 0001288952
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Wells Fargo initiates coverage on Hamilton Lane with Overweight rating. Wells Fargo has started covering Hamilton Lane, assigning an Overweight rating and a price target of $103. This new analyst view comes as the company prepares to report second-quarter results in November. Additionally, attention is turning to the planned 2027 retirement of a key executive, which may influence long-term expectations for the firm.
Transaction History
| PTCT | ▼ Sell | Open Market | 2,447 | $155K | 10/7/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 53 | $3K | 10/7/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 9,624 | $653K | 9/17/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 376 | $26K | 9/17/2026 | View on chart |
| HLNE | ▲ Buy | Grant | 977 | $0 | 9/16/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 2,994 | $199K | 9/16/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 7,006 | $472K | 9/16/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 10,000 | $673K | 9/10/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 572 | $39K | 9/9/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 9,428 | $639K | 9/9/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 11,890 | $851K | 8/27/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 610 | $44K | 8/27/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 6,874 | $500K | 8/26/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 5,626 | $412K | 8/26/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 9,419 | $667K | 8/20/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 2,390 | $172K | 8/20/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 691 | $50K | 8/20/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 5,335 | $389K | 8/19/2026 | View on chart |
| PTCT | ▼ Sell | Open Market | 7,165 | $528K | 8/19/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 8,000 | $0 | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 24,000 | $741K | 12/16/2025 | View on chart |
| HLNE | ▼ Sell | Other | 25,005 | $25 | 9/4/2025 | View on chart |
| HLNE | ▼ Sell | Other | 100,000 | $100 | 2/12/2025 | View on chart |
| PTCT | ▲ Buy | Grant | 8,000 | $0 | 1/3/2025 | View on chart |
| PTCT | ▲ Buy | Grant | 8,000 | $0 | 2/15/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 1,500 | $42K | 1/8/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 1,000 | $45K | 6/7/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 8,000 | $0 | 1/5/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29
PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.